US equities |
NVDA $186.39 ▼-6.87% MU $692.07 ▼-12.97% TSLA $350.24 ▼-9.07% SPCX $125.60 ▼-7.59% AAPL $347.11 ▼-0.69% AMZN $259.31 ▼-2.53% AMD $415.38 ▼-15.02% META $608.88 ▼-3.35%
FinancialContent

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

50.67 -1.75 (-3.33%)
Delayed Quote Updated: 11:27 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Third Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Third Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Planned Chief Executive Officer Transition
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Second Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports First Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report First Quarter 2026 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >